Funding This work is funded by Cancer Research UK and administered through the Manchester Cancer Research Centre Leeds-Manchester Collaboration PhD scheme (SEBCATP-2023/100010)
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open label phase II trial
The most frequent adverse effects are gastrointestinal and dose-related: Nausea, vomiting, diarrhoea, constipation, and abdominal discomfort - Typically worst during dose escalation and often resolve or attenuate with continued treatment and slower titration
Women tell us that the structure makes it easier to stay consistent even on busy weeks because they do not have to guess what to train
This does not mean the microbiome is the sole factor in how well semaglutide works, but it does suggest that the microbial environment in your gut may be one meaningful piece of the broader metabolic picture
When individuals consistently take GLP-1 medication as directed by their healthcare provider, the medication can work more efficiently in reducing hunger and aiding weight loss
